New chemo cocktail aims to tackle rare brain tumors
NCT ID NCT07188441
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two chemotherapy drugs, teniposide and cisplatin, in 40 people newly diagnosed with central malignant germ cell tumors. The goal is to see if the combo is safe and effective at shrinking tumors and prolonging survival. Researchers will also look for biomarkers that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teniposide and cisplatin
What this could lead to
If successful, this combination could offer a new treatment option to control central malignant germ cell tumors and extend survival.
What could go wrong
This is a small, early-phase trial with only 40 participants and no comparison group, so results may not be definitive. Side effects from chemotherapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GCT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••